Jasvinder A Singh1, Gordon Guyatt2, Alexis Ogdie3, Dafna D Gladman4, Chad Deal5, Atul Deodhar6, Maureen Dubreuil7, Jonathan Dunham3, M Elaine Husni5, Sarah Kenny8, Jennifer Kwan-Morley9, Janice Lin10, Paula Marchetta11, Philip J Mease12, Joseph F Merola13, Julie Miner14, Christopher T Ritchlin15, Bernadette Siaton16, Benjamin J Smith17, Abby S Van Voorhees18, Anna Helena Jonsson13, Amit Aakash Shah19, Nancy Sullivan20, Marat Turgunbaev19, Laura C Coates21, Alice Gottlieb22, Marina Magrey23, W Benjamin Nowell24, Ana-Maria Orbai25, Soumya M Reddy26, Jose U Scher26, Evan Siegel27, Michael Siegel28, Jessica A Walsh29, Amy S Turner19, James Reston20. 1. University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama. 2. McMaster University, Hamilton, Ontario, Canada. 3. University of Pennsylvania, Philadelphia. 4. University of Toronto and Toronto Western Hospital, Toronto, Ontario, Canada. 5. Cleveland Clinic, Cleveland, Ohio. 6. Oregon Health & Science University, Portland. 7. Boston Medical Center, Boston, Massachusetts. 8. New York, New York. 9. Premier Orthopaedics, Malvern, Pennsylvania. 10. Stanford University, Stanford, California. 11. Concorde Medical Group, New York, New York. 12. Swedish-Providence Health Systems and University of Washington, Seattle, Washington. 13. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 14. Comprehensive Therapy Consultants and Therapy Steps, Roswell, Georgia. 15. University of Rochester Medical Center, Rochester, New York. 16. University of Maryland School of Medicine, Baltimore. 17. Florida State University College of Medicine School of Physician Assistant Practice, Tallahassee. 18. Eastern Virginia Medical School, Norfolk. 19. American College of Rheumatology, Atlanta, Georgia. 20. ECRI Institute, Plymouth Meeting, Pennsylvania. 21. University of Oxford, Oxford, UK. 22. New York Medical College at Metropolitan Hospital, New York, New York. 23. Case Western/MetroHealth, Cleveland, Ohio. 24. Global Healthy Living Foundation, Nyack, New York. 25. Johns Hopkins University, Baltimore, Maryland. 26. New York University School of Medicine, New York, New York. 27. Arthritis & Rheumatism Associates, Rockville, Maryland. 28. National Psoriasis Foundation, Portland, Oregon. 29. University of Utah and George E. Wahlen VeteranS Affairs Medical Center, Salt Lake City, Utah.
Abstract
OBJECTIVE: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF). METHODS: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of the evidence. A voting panel, including rheumatologists, dermatologists, other health professionals, and patients, achieved consensus on the direction and the strength of the recommendations. RESULTS: The guideline covers the management of active PsA in patients who are treatment-naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitors (IL-12/23i), IL-17 inhibitors, CTLA4-Ig (abatacept), and a JAK inhibitor (tofacitinib). We also developed recommendations for psoriatic spondylitis, predominant enthesitis, and treatment in the presence of concomitant inflammatory bowel disease, diabetes, or serious infections. We formulated recommendations for a treat-to-target strategy, vaccinations, and nonpharmacologic therapies. Six percent of the recommendations were strong and 94% conditional, indicating the importance of active discussion between the health care provider and the patient to choose the optimal treatment. CONCLUSION: The 2018 ACR/NPF PsA guideline serves as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Best treatment decisions consider each individual patient situation. The guideline is not meant to be proscriptive and should not be used to limit treatment options for patients with PsA.
OBJECTIVE: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF). METHODS: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of the evidence. A voting panel, including rheumatologists, dermatologists, other health professionals, and patients, achieved consensus on the direction and the strength of the recommendations. RESULTS: The guideline covers the management of active PsA in patients who are treatment-naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitors (IL-12/23i), IL-17 inhibitors, CTLA4-Ig (abatacept), and a JAK inhibitor (tofacitinib). We also developed recommendations for psoriatic spondylitis, predominant enthesitis, and treatment in the presence of concomitant inflammatory bowel disease, diabetes, or serious infections. We formulated recommendations for a treat-to-target strategy, vaccinations, and nonpharmacologic therapies. Six percent of the recommendations were strong and 94% conditional, indicating the importance of active discussion between the health care provider and the patient to choose the optimal treatment. CONCLUSION: The 2018 ACR/NPF PsA guideline serves as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Best treatment decisions consider each individual patient situation. The guideline is not meant to be proscriptive and should not be used to limit treatment options for patients with PsA.
Authors: Howard Balshem; Mark Helfand; Holger J Schünemann; Andrew D Oxman; Regina Kunz; Jan Brozek; Gunn E Vist; Yngve Falck-Ytter; Joerg Meerpohl; Susan Norris; Gordon H Guyatt Journal: J Clin Epidemiol Date: 2011-01-05 Impact factor: 6.437
Authors: Jeff Andrews; Gordon Guyatt; Andrew D Oxman; Phil Alderson; Philipp Dahm; Yngve Falck-Ytter; Mona Nasser; Joerg Meerpohl; Piet N Post; Regina Kunz; Jan Brozek; Gunn Vist; David Rind; Elie A Akl; Holger J Schünemann Journal: J Clin Epidemiol Date: 2013-01-09 Impact factor: 6.437
Authors: Alice Gottlieb; Alan Menter; Alan Mendelsohn; Yaung-Kaung Shen; Shu Li; Cynthia Guzzo; Scott Fretzin; Rod Kunynetz; Arthur Kavanaugh Journal: Lancet Date: 2009-02-11 Impact factor: 79.321
Authors: Maurizio Cutolo; Gary E Myerson; Roy M Fleischmann; Frédéric Lioté; Federico Díaz-González; Filip Van den Bosch; Helena Marzo-Ortega; Eugen Feist; Kamal Shah; ChiaChi Hu; Randall M Stevens; Airi Poder Journal: J Rheumatol Date: 2016-07-15 Impact factor: 4.666
Authors: Mark C Genovese; Philip J Mease; Glen T D Thomson; Alan J Kivitz; Renee J Perdok; Mark A Weinberg; John Medich; Eric H Sasso Journal: J Rheumatol Date: 2007-04-15 Impact factor: 4.666
Authors: Ute Mons; Aysel Müezzinler; Carolin Gellert; Ben Schöttker; Christian C Abnet; Martin Bobak; Lisette de Groot; Neal D Freedman; Eugène Jansen; Frank Kee; Daan Kromhout; Kari Kuulasmaa; Tiina Laatikainen; Mark G O'Doherty; Bas Bueno-de-Mesquita; Philippos Orfanos; Annette Peters; Yvonne T van der Schouw; Tom Wilsgaard; Alicja Wolk; Antonia Trichopoulou; Paolo Boffetta; Hermann Brenner Journal: BMJ Date: 2015-04-20
Authors: Philip J Mease; Alice B Gottlieb; Désirée van der Heijde; Oliver FitzGerald; Alyssa Johnsen; Marleen Nys; Subhashis Banerjee; Dafna D Gladman Journal: Ann Rheum Dis Date: 2017-05-04 Impact factor: 19.103
Authors: Philip J Mease; Alexis Ogdie; Soumya D Chakravarty; Natalie J Shiff; Iris Lin; Robert R McLean; Wendi Malley; Rebecca L Spitzer; Arthur Kavanaugh; Joseph F Merola Journal: Drugs Real World Outcomes Date: 2022-10-15
Authors: Christopher T Ritchlin; Mona Stahle; Yves Poulin; Jerry Bagel; Soumya D Chakravarty; Shelly Kafka; Bhaskar Srivastava; Wayne Langholff; Alice B Gottlieb Journal: BMC Rheumatol Date: 2019-11-28